Khaitan & Co. acted as the domestic legal counsel to the Book Running Lead Managers on the deal. Knowledge Realty Trust (A Blackstone-Sattva joint venture REIT)...
You must be a Standard 1 Year member to access this content.
Khaitan & Co acted as the legal counsel for RPG Life Sciences Limited on the deal. RPG Life Sciences Limited sold a 3.7-acre MIDC leasehold land...
You must be a Standard 1 Year member to access this content.
Khaitan & Co acted as the legal counsel for Jupiter Life Line Hospitals Limited on the deal. Jupiter Life Line Hospitals Limited finalized the acquisition of...
You must be a Standard 1 Year member to access this content.
Khaitan & Co advised Innovate Advisors on the deal. Innovate Advisors finalized the acquisition of 4 Acres of land parcel in a prime location of Wagholi,...
You must be a Standard 1 Year member to access this content.
Khaitan & Co advised Nirma Limited on the deal. Nirma Limited completed the acquisition of a majority stake of 75% in Glenmark Life Sciences Limited from Glenmark...
You must be a Standard 1 Year member to access this content.
Ashurst advises social enterprise Givfunds on FCA registration. Givfunds Social Ventures obtained the registration with the Financial Conduct Authority (FCA). Givfunds, a social enterprise, works to bridge...
You must be a Standard 1 Year member to access this content.
Khaitan & Co acted as the legal adviser to Asset Care & Reconstruction Enterprise Limited (ACRE). Asset Care & Reconstruction Enterprise Limited (ACRE), which was backed...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented the underwriters in the IPO while Goodwin advised PepGen. PepGen, Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal while Goodwin Procter represented Amylyx Pharmaceuticals. Amylyx Pharmaceuticals, Inc. (“Amylyx”), a clinical-stage pharmaceutical company...
You must be a Standard 1 Year member to access this content.
Goodwin advised Korro Bio on the deal. Korro Bio, Inc. announced its $116 million Series B financing. Korro is an RNA editing company focused on discovery...
You must be a Standard 1 Year member to access this content.
